Validated using a knockout cell line
Recombinant
RabMAb

Recombinant Anti-non-muscle Myosin IIA antibody [EPR8965] (HRP) (ab205470)

Overview

  • Product name
    Anti-non-muscle Myosin IIA antibody [EPR8965] (HRP)
    See all non-muscle Myosin IIA primary antibodies
  • Description
    Rabbit monoclonal [EPR8965] to non-muscle Myosin IIA (HRP)
  • Host species
    Rabbit
  • Conjugation
    HRP
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity

    Predicted to work with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human non-muscle Myosin IIA aa 1900 to the C-terminus. The exact sequence is proprietary.
    Database link: P35579

  • Positive control
    • WB: Jurkat and A431 whole cell and human fetal kidney tissue lysates.
  • General notes

    Alternative versions available:
    Anti-non-muscle Myosin IIA antibody [EPR8965] (ab138498) Knockout validated

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
  • Storage buffer
    pH: 7.40
    Preservative: 0.1% Proclin
    Constituents: 30% Glycerol, 1% BSA, PBS
  • Concentration information loading...
  • Purity
    Affinity purified
  • Clonality
    Monoclonal
  • Clone number
    EPR8965
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab205470 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 230 kDa (predicted molecular weight: 227 kDa).

Target

  • Function
    Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.
  • Tissue specificity
    In the kidney, expressed in the glomeruli. Also expressed in leukocytes.
  • Involvement in disease
    Defects in MYH9 are the cause of May-Hegglin anomaly (MHA) [MIM:155100]. MHA is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukokyte inclusions appearing as highly parallel paracrystalline bodies.
    Defects in MYH9 are the cause of Sebastian syndrome (SBS) [MIM:605249]. SBS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are smaller and less organized than in May-Hegglin anomaly.
    Defects in MYH9 are the cause of Fechtner syndrome (FTNS) [MIM:153640]. FTNS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are small and poorly organized. Additionally, FTNS is distinguished by Alport-like clinical features of sensorineural deafness, cataracts and nephritis.
    Defects in MYH9 are the cause of Alport syndrome with macrothrombocytopenia (APSM) [MIM:153650]. APSM is an autosomal dominant disorder characterized by the association of ocular lesions, sensorineural hearing loss and nephritis (Alport syndrome) with platelet defects.
    Defects in MYH9 are the cause of Epstein syndrome (EPS) [MIM:153650]. EPS is an autosomal dominant disorder characterized by the association of macrothrombocytopathy, sensorineural hearing loss and nephritis.
    Defects in MYH9 are the cause of deafness autosomal dominant type 17 (DFNA17) [MIM:603622]. DFNA17 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA17 is characterized by progressive hearing impairment and cochleosaccular degeneration.
    Defects in MYH9 are the cause of macrothrombocytopenia with progressive sensorineural deafness (MPSD) [MIM:600208]. MPSD is an autosomal dominant disorder characterized by the association of macrothrombocytopathy and progressive sensorineural hearing loss without renal dysfunction.
    Note=Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.
    Note=Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD).
  • Sequence similarities
    Contains 1 IQ domain.
    Contains 1 myosin head-like domain.
  • Domain
    The rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.
  • Post-translational
    modifications
    ISGylated.
  • Information by UniProt
  • Database links
  • Alternative names
    • BDPLT 6 antibody
    • BDPLT6 antibody
    • Cellular myosin heavy chain antibody
    • Cellular myosin heavy chain type A antibody
    • DFNA 17 antibody
    • DFNA17 antibody
    • EPSTS antibody
    • FTNS antibody
    • MGC104539 antibody
    • MHA antibody
    • MYH 2A antibody
    • MYH 9 antibody
    • MYH2A antibody
    • MYH9 antibody
    • MYH9_HUMAN antibody
    • MYHas8 antibody
    • MyHC 2A antibody
    • MyHC IIa antibody
    • MyHC2A antibody
    • MyHCIIa antibody
    • MYHSA 2 antibody
    • MYHSA2 antibody
    • Myosin 9 antibody
    • Myosin heavy chain 9 antibody
    • Myosin heavy chain 9 non muscle antibody
    • Myosin heavy chain antibody
    • Myosin heavy chain non muscle IIa antibody
    • Myosin heavy chain nonmuscle IIa antibody
    • Myosin heavy polypeptide 2 antibody
    • Myosin heavy polypeptide 9 non muscle antibody
    • Myosin-9 antibody
    • Myosin9 antibody
    • NMHC II A antibody
    • NMMHC A antibody
    • NMMHC II a antibody
    • NMMHC II-a antibody
    • NMMHC IIA antibody
    • NMMHC-A antibody
    • NMMHC-IIA antibody
    • NMMHCA antibody
    • Non muscle myosin heavy chain A antibody
    • Non muscle myosin heavy chain antibody
    • Non muscle myosin heavy chain II A antibody
    • Non muscle myosin heavy polypeptide 9 antibody
    • non-muscle IIa antibody
    • Non-muscle myosin heavy chain A antibody
    • Non-muscle myosin heavy chain IIa antibody
    • Nonmuscle myosin heavy chain A antibody
    • Nonmuscle myosin heavy chain II A antibody
    • type A antibody
    see all

Images

  • All lanes : Anti-non-muscle Myosin IIA antibody [EPR8965] (HRP) (ab205470) at 1/5000 dilution

    Lane 1 : Wild-type HAP1 whole cell lysate
    Lane 2 : MYH9 (non-muscle Myosin IIA) knockout HAP1 whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Predicted band size: 227 kDa
    Observed band size: 230 kDa
    why is the actual band size different from the predicted?


    Exposure time: 20 seconds


    ab205470 was shown to specifically react with non-muscle Myosin IIA in wild-type HAP1 cells as signal was lost in MYH9 (non-muscle Myosin IIA) knockout cells. Wild-type and MYH9 (non-muscle Myosin IIA) knockout samples were subjected to SDS-PAGE. Ab205470 and ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/5000 dilution and 1/20000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.

  • All lanes : Anti-non-muscle Myosin IIA antibody [EPR8965] (HRP) (ab205470) at 1/5000 dilution

    Lane 1 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
    Lane 2 : Kidney (Human) Tissue Lysate - fetal normal tissue
    Lane 3 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 227 kDa
    Observed band size: 230 kDa why is the actual band size different from the predicted?


    Exposure time: 15 seconds


    This blot was produced using a 3-8% Tris Acetate gel under the TA buffer system. The gel was run at 150V for 60 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab205470 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab205470 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab205470.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
For licensing inquiries, please contact partnerships@abcam.com

Sign up